Oncopeptides Ab Stock Market Capitalization
| ONCO Stock | SEK 2.98 0.06 2.05% |
Oncopeptides AB fundamentals help investors to digest information that contributes to Oncopeptides' financial success or failures. It also enables traders to predict the movement of Oncopeptides Stock. The fundamental analysis module provides a way to measure Oncopeptides' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncopeptides stock.
Oncopeptides |
Oncopeptides AB Company Market Capitalization Analysis
Oncopeptides' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Oncopeptides Market Capitalization | 933.96 M |
Most of Oncopeptides' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncopeptides AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Oncopeptides AB is about 933.96 M. This is 92.78% lower than that of the Biotechnology sector and 80.3% lower than that of the Health Care industry. The market capitalization for all Sweden stocks is 95.09% higher than that of the company.
Oncopeptides Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncopeptides' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncopeptides could also be used in its relative valuation, which is a method of valuing Oncopeptides by comparing valuation metrics of similar companies.Oncopeptides is currently under evaluation in market capitalization category among related companies.
Oncopeptides Fundamentals
| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 | |||
| Operating Margin | 49.84 % | |||
| Current Valuation | 776.19 M | |||
| Shares Outstanding | 90.37 M | |||
| Shares Owned By Insiders | 10.76 % | |||
| Shares Owned By Institutions | 47.54 % | |||
| Price To Book | 2.96 X | |||
| Price To Sales | 34.76 X | |||
| Revenue | 118.3 M | |||
| Gross Profit | 74.16 M | |||
| EBITDA | (1.41 B) | |||
| Net Income | (1.43 B) | |||
| Cash And Equivalents | 747.47 M | |||
| Cash Per Share | 15.30 X | |||
| Debt To Equity | 1.20 % | |||
| Current Ratio | 7.97 X | |||
| Book Value Per Share | 4.21 X | |||
| Cash Flow From Operations | (1.52 B) | |||
| Earnings Per Share | (16.78) X | |||
| Target Price | 26.67 | |||
| Number Of Employees | 40 | |||
| Beta | -0.67 | |||
| Market Capitalization | 933.96 M | |||
| Total Asset | 439.38 M | |||
| Z Score | -9.9 | |||
| Net Asset | 439.38 M |
About Oncopeptides Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncopeptides AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncopeptides using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncopeptides AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncopeptides AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Oncopeptides Stock analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |